| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Diabetes Branch (M.P., D.L.), National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892; Department of Biological Chemistry (A.G., A.L.), Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem 91904, Israel; and Department of Pathology (E.W.), Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978 Israel
Address all correspondence and requests for reprints to: Derek LeRoith, Diabetes Branch, NIDDK, NIH, Building 10, Room 8S235A, 10 Center Drive, MSC-1770, Bethesda, Maryland 20892-1770. E-mail: Derek{at}helix.nih.gov
A series of the synthetic protein tyrosine kinase inhibitors known as tyrphostins were studied for their effect on insulin-like growth factor-1 and insulin-stimulated cellular proliferation on NIH-3T3 fibroblasts overexpressing either receptor, as well as for their ability to inhibit ligand-stimulated receptor autophosphorylation and tyrosine kinase activity toward exogenous substrates. Several of the tyrphostins tested demonstrated a dramatic effect by inhibiting hormone-stimulated cell proliferation, with IC50s in the submicromolar range, while being unable to block serum-stimulated cell proliferation. The tyrphostins also inhibited receptor autophosphorylation and tyrosine kinase activity, with a higher IC50, in the micromolar range. Most of the tyrphostins tested presented no clear preference for either receptor, although two of them (AG1024 and AG1034) showed significantly lower IC50s for IGF-1 than for insulin receptors. These results suggest that, in spite of the high homology of the kinase regions of both receptors, it could be possible to design and synthesize small molecules capable of discriminating between them. The synthesis of such specific inhibitors could be an excellent tool to establish the precise signalling mechanisms that distinguish between the different effects of these two hormones.
This article has been cited by other articles:
 |
|
 |
|
  W.-Q. Zhao, P. N. Lacor, H. Chen, M. P. Lambert, M. J. Quon, G. A. Krafft, and W. L. Klein Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric A{beta} J. Biol. Chem., July 10, 2009; 284(28): 18742 - 18753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Litzenburger, H.-J. Kim, I. Kuiatse, J. M. Carboni, R. M. Attar, M. M. Gottardis, C. R. Fairchild, and A. V. Lee BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells Clin. Cancer Res., January 1, 2009; 15(1): 226 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Fiedler, E. Schonherr, R. Waddington, S. Niland, D. G. Seidler, D. Aeschlimann, and J. A. Eble Decorin Regulates Endothelial Cell Motility on Collagen I through Activation of Insulin-like Growth Factor I Receptor and Modulation of {alpha}2{beta}1 Integrin Activity J. Biol. Chem., June 20, 2008; 283(25): 17406 - 17415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sachdev and D. Yee Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 39 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kim, A. Garcia, S. P. Jackson, and S. P. Kunapuli Insulin-like growth factor-1 regulates platelet activation through PI3-K{alpha} isoform Blood, December 15, 2007; 110(13): 4206 - 4213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Edderkaoui, P. Hong, J. K. Lee, S. J. Pandol, and A. S. Gukovskaya Insulin-like Growth Factor-I Receptor Mediates the Prosurvival Effect of Fibronectin J. Biol. Chem., September 14, 2007; 282(37): 26646 - 26655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bunda, P. Liu, Y. Wang, K. Liu, and A. Hinek Aldosterone Induces Elastin Production in Cardiac Fibroblasts through Activation of Insulin-Like Growth Factor-I Receptors in a Mineralocorticoid Receptor-Independent Manner Am. J. Pathol., September 1, 2007; 171(3): 809 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Lauzier, E. L. Page, M. D. Michaud, and D. E. Richard Differential Regulation of Hypoxia-Inducible Factor-1 through Receptor Tyrosine Kinase Transactivation in Vascular Smooth Muscle Cells Endocrinology, August 1, 2007; 148(8): 4023 - 4031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. X.-D. Song, Z. Zhang, Y. Chen, Y. Bao, and R. J. Santen Estrogen Signaling via a Linear Pathway Involving Insulin-Like Growth Factor I Receptor, Matrix Metalloproteinases, and Epidermal Growth Factor Receptor to Activate Mitogen-Activated Protein Kinase in MCF-7 Breast Cancer Cells Endocrinology, August 1, 2007; 148(8): 4091 - 4101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bose, M A. Farah, H.-C. Jung, J.-H. Lee, and Y. Kim Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone J. Mol. Endocrinol., June 1, 2007; 38(6): 627 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Martin and R. C. Baxter Expression of Insulin-Like Growth Factor Binding Protein-2 by MCF-7 Breast Cancer Cells Is Regulated through the Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway Endocrinology, May 1, 2007; 148(5): 2532 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Morgillo, W.-Y. Kim, E. S. Kim, F. Ciardiello, W. K. Hong, and H.-Y. Lee Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non small Cell Lung Cancer Cells to Treatment with Gefitinib Clin. Cancer Res., May 1, 2007; 13(9): 2795 - 2803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, A. M. Pelzer, D. T. Kiang, and D. Yee Down-regulation of Type I Insulin-like Growth Factor Receptor Increases Sensitivity of Breast Cancer Cells to Insulin Cancer Res., January 1, 2007; 67(1): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sachdev and D. Yee Disrupting insulin-like growth factor signaling as a potential cancer therapy Mol. Cancer Ther., January 1, 2007; 6(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Morgillo, J. K. Woo, E. S. Kim, W. K. Hong, and H.-Y. Lee Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib. Cancer Res., October 15, 2006; 66(20): 10100 - 10111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sachdev, R. Singh, Y. Fujita-Yamaguchi, and D. Yee Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti-Insulin-Like Growth Factor Therapy in Breast Cancer Cancer Res., February 15, 2006; 66(4): 2391 - 2402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Haluska, J. M. Carboni, D. A. Loegering, F. Y. Lee, M. Wittman, M. G. Saulnier, D. B. Frennesson, K. R. Kalli, C. A. Conover, R. M. Attar, et al. In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417 Cancer Res., January 1, 2006; 66(1): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor Endocrinology, November 1, 2005; 146(11): 4609 - 4618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Blanquart, N. Boute, D. Lacasa, and T. Issad Monitoring the Activation State of the Insulin-Like Growth Factor-1 Receptor and Its Interaction with Protein Tyrosine Phosphatase 1B Using Bioluminescence Resonance Energy Transfer Mol. Pharmacol., September 1, 2005; 68(3): 885 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, J. Hailey, D. Williams, Y. Wang, P. Lipari, M. Malkowski, X. Wang, L. Xie, G. Li, D. Saha, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody Mol. Cancer Ther., August 1, 2005; 4(8): 1214 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-C. Lee, C.-C. Huang, M.-Y. Wu, and K.-S. Hsu Insulin Stimulates Postsynaptic Density-95 Protein Translation via the Phosphoinositide 3-Kinase-Akt-Mammalian Target of Rapamycin Signaling Pathway J. Biol. Chem., May 6, 2005; 280(18): 18543 - 18550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ster, C. Colomer, C. Monzo, A. Duvoid-Guillou, F. Moos, G. Alonso, and N. Hussy Insulin-Like Growth Factor-1 Inhibits Adult Supraoptic Neurons via Complementary Modulation of Mechanoreceptors and Glycine Receptors J. Neurosci., March 2, 2005; 25(9): 2267 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Ibrahim and D. Yee Insulin-Like Growth Factor-I and Breast Cancer Therapy Clin. Cancer Res., January 15, 2005; 11(2): 944s - 950s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, and R I Nicholson Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr. Relat. Cancer, December 1, 2004; 11(4): 793 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shiiki, S. Ohtsuki, A. Kurihara, H. Naganuma, K. Nishimura, M. Tachikawa, K.-i. Hosoya, and T. Terasaki Brain Insulin Impairs Amyloid-{beta}(1-40) Clearance from the Brain J. Neurosci., October 27, 2004; 24(43): 9632 - 9637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zahradka, B. Litchie, B. Storie, and G. Helwer Transactivation of the Insulin-Like Growth Factor-I Receptor by Angiotensin II Mediates Downstream Signaling from the Angiotensin II Type 1 Receptor to Phosphatidylinositol 3-Kinase Endocrinology, June 1, 2004; 145(6): 2978 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. X. Song, C. J. Barnes, Z. Zhang, Y. Bao, R. Kumar, and R. J. Santen The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor {alpha} to the plasma membrane PNAS, February 17, 2004; 101(7): 2076 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Girnita, L. Girnita, F. d. Prete, A. Bartolazzi, O. Larsson, and M. Axelson Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth Cancer Res., January 1, 2004; 64(1): 236 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Blum, A. Gazit, and A. Levitzki Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics J. Biol. Chem., October 17, 2003; 278(42): 40442 - 40454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Maloney, J. L. McLaughlin, N. E. Dagdigian, L. M. Garrett, K. M. Connors, X.-M. Zhou, W. A. Blattler, T. Chittenden, and R. Singh An Anti-Insulin-like Growth Factor I Receptor Antibody That Is a Potent Inhibitor of Cancer Cell Proliferation Cancer Res., August 15, 2003; 63(16): 5073 - 5083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. von Willebrand, E. Zacksenhaus, E. Cheng, P. Glazer, and R. Halaban The Tyrphostin AG1024 Accelerates the Degradation of Phosphorylated Forms of Retinoblastoma Protein (pRb) and Restores pRb Tumor Suppressive Function in Melanoma Cells Cancer Res., March 15, 2003; 63(6): 1420 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Gunton, P. J. D. Delhanty, S.-I. Takahashi, and R. C. Baxter Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2 J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1323 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sachdev, S.-L. Li, J. S. Hartell, Y. Fujita-Yamaguchi, J. S. Miller, and D. Yee A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I Cancer Res., February 1, 2003; 63(3): 627 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rizzo, M. A. Magnuson, P. F. Drain, and D. W. Piston A Functional Link between Glucokinase Binding to Insulin Granules and Conformational Alterations in Response to Glucose and Insulin J. Biol. Chem., September 6, 2002; 277(37): 34168 - 34175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang and D. Yee Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) Inhibits Breast Cancer Cell Motility Cancer Res., August 1, 2002; 62(15): 4369 - 4375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Grant, M. B. Ross, S. Ballard, A. Naylor, and F. K. Habib The Insulin-Like Growth Factor Type I Receptor Stimulates Growth and Suppresses Apoptosis in Prostatic Stromal Cells J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3252 - 3257. [Abstract] [Full Text]
|
|
|
|
|
|
A. P. Koval, M. Karas, Y. Zick, and D. LeRoith Interplay of the Proto-oncogene Proteins CrkL and CrkII in Insulin-like Growth Factor-I Receptor-mediated Signal Transduction J. Biol. Chem., June 12, 1998; 273(24): 14780 - 14787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Foncea, M. Andersson, A. Ketterman, V. Blakesley, M. Sapag-Hagar, P. H. Sugden, D. LeRoith, and S. Lavandero Insulin-like Growth Factor-I Rapidly Activates Multiple Signal Transduction Pathways in Cultured Rat Cardiac Myocytes J. Biol. Chem., August 1, 1997; 272(31): 19115 - 19124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Kuemmerle and K. S. Murthy Coupling of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase to Gi2 in Human Intestinal Smooth Muscle. Gbeta gamma -DEPENDENT MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION AND GROWTH J. Biol. Chem., March 2, 2001; 276(10): 7187 - 7194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Khatib, G. Siegfried, A. Prat, J. Luis, M. Chretien, P. Metrakos, and N. G. Seidah Inhibition of Proprotein Convertases Is Associated with Loss of Growth and Tumorigenicity of HT-29 Human Colon Carcinoma Cells. IMPORTANCE OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) RECEPTOR PROCESSING IN IGF-1-MEDIATED FUNCTIONS J. Biol. Chem., August 10, 2001; 276(33): 30686 - 30693. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
